On February 2, U.S.-based private equity firm RoundTable Healthcare Partners, which specializes exclusively in the healthcare sector, announced an investment and strategic partnership with premium skincare and sun protection brand Colorescience. The terms of the transaction were not disclosed.
Founded on a science-driven approach, Colorescience is known for its mineral-based, clinically validated formulations that combine broad-spectrum sun protection with cosmetically elegant finishes. The brand has earned strong credibility among dermatologists, plastic surgeons, aestheticians, and medical spas by integrating scientific evidence with products designed for daily use.
Expanding Business Through an Omnichannel Strategy
The company operates a diversified omnichannel model that includes professional channels, direct-to-consumer sales, and leading e-commerce platforms. Following a period of robust growth, Colorescience is positioned to further expand brand awareness, accelerate penetration across sales channels, and broaden its product portfolio while maintaining its clinical heritage.
Executive Commentary on the Brand’s Next Phase
Mary Fisher, Chief Executive Officer of Colorescience, commented: “Since 2013, our team has built Colorescience into a trusted brand that delivers meaningful protection and performance for our customers. I want to sincerely thank our employees for their passion and dedication in helping us reach this exciting point in our evolution. We are thrilled to partner with RoundTable as we enter the next stage of growth, and we believe their values, culture, and operating expertise align closely with what makes Colorescience special.”
Tim Connors, Managing Partner of RoundTable and Chairman of Colorescience’s Board, added: “Colorescience has built a compelling platform defined by strong consumer advocacy and a differentiated product portfolio anchored by a commitment to science and innovation. We look forward to supporting the team as they continue to advance the Colorescience brand and capitalize on the Company’s momentum.”
Investment Rationale and Fund Strategy
Jawwad Akhtar, Partner at RoundTable, described the strategic importance of the investment: “Colorescience represents our ninth consumer healthcare platform investment. It reinforces RoundTable’s commitment to partnering with management teams to build enduring, category-leading businesses with brands that are both expert-recommended and consumer-preferred. We believe our dedicated operating resources, channel expertise, and experience supporting practitioner-oriented brands position us well to help the Company accelerate growth and better serve its customers.”
Colorescience was acquired from a shareholder group led by 1315 Capital. Adele Oliva, Founding Partner of 1315 Capital, reflected on the partnership: “It has been a privilege to work alongside the Colorescience team as the Company focused on protecting and saving lives through its high-performing skincare and sun protection products. We have partnered with RoundTable on multiple transactions and have been consistently impressed with their operational focus. The growth of Colorescience over the past few years has been tremendous, and we are excited about RoundTable’s impact on the trajectory ahead.”
Financing and Advisory Structure
The transaction marks RoundTable’s third platform investment from its $800 million Equity Fund VI. Senior debt financing was provided by Capital One, N.A. as Sole Lead Arranger and Administrative Agent, with participation from CIBC Bank USA and Lord Abbett Private Credit Advisor LLC. Legal and financial advisors on the transaction included Sidley Austin LLP, Raymond James, and Greenberg Traurig, LLP.
Copyright © 2026 Oui Speak Fashion. All rights reserved.